Bicycle Therapeutics plc
BCYC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.05 | -0.13 | 0.00 |
| FCF Yield | -13.39% | -15.23% | -14.86% | -1.01% |
| EV / EBITDA | 1.86 | 3.00 | 2.80 | -1.47 |
| Quality | ||||
| ROIC | -9.37% | -11.36% | -8.29% | -7.40% |
| Gross Margin | 100.00% | -2,332.50% | -474.03% | -1,412.19% |
| Cash Conversion Ratio | 1.20 | 0.92 | 1.42 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.50% | -5.04% | 18.40% | 34.61% |
| Free Cash Flow Growth | 1.96% | 16.06% | -794.18% | 75.75% |
| Safety | ||||
| Net Debt / EBITDA | 11.25 | 9.21 | 11.17 | 13.19 |
| Interest Coverage | -1,489.80 | -1,603.74 | -1,376.55 | -1,301.21 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 515.91 | 1,849.38 | 400.87 | 840.02 |